FLT3 and acute myeloid leukemia: Based on the positive experiences of combining FLT3 inhibitors (midostaurin, sorafenib, gilteritinib) with chemotherapy from pilot studies and from the German and Intergroup randomized trials (discussed later), this approach may become a standard of care in FLT3- mutated AML, but also perhaps in all patients with AML regardless of FLT3 mutation status.